Views & Analysis | Perspectives on pharma industry issues

Oncology

In vivo CAR-T can solve the delivery problem – but solid tum...

A new generation of in vivo CAR-T cell technologies promises to remove some of the biggest practical barriers to conventional cell therapy.

Oncology

Unlocking the scalability of allogeneic CAR-T

Allogeneic CAR-T, built from healthy donor T-cells, offers a different path toward scale, accessibility, and consistency.

R&D

Why every healthcare breakthrough creates a new education ch...

Patients will only benefit from a health breakthrough if HCPs and the systems around them are able to put it into practice.

Sales & Marketing

Female HCP in her office on phone holding clipboard of patient information

Sponsored

Commercial Evidence: Turning field intelligence into actiona...

Agentic Call Reports help turn field observations into scalable, actionable insights generating Commercial Evidence.

Digital

Healthcare AI’s off switch needs a budget

An AI system can be cheap to buy and expensive to stop.

Articles

Lessons from the past, optimism for the future

In our latest interview Paul Tunnah talks to Nigel Brooksby, a well known figure in UK pharma, to hear his advice for the next generation of industry leaders. One could be forgiven sometimes for thinking that there has never been a more challenging time to work in the pharma industry...

Articles

What Are IDEAs Made Of: Workshop roles

In this week’s WAIMO, Mike Rea explores the concept of the Idea Killer, the single most deadly destroyer of innovation and creativity. When pushed, most of us believe that we're better-than-average idea evaluators. However, when pushed further...

Articles

Selling to pharma: a view from the service sector

As pharma now engages multiple customer groups with varying needs, Jon Heeks asks whether industry execs might find the service sector to be a more familiar place. It is likely that many managers in the pharmaceutical industry have thought about the possibility of a pursuing a career with...

Sales & Marketing

Sponsored

Commercial Evidence: Turning field intelligence into actiona...

Agentic Call Reports help turn field observations into scalable, actionable insights generating Commercial Evidence.

Sales & Marketing

The independent pharmacy opportunity pharma marketers are ov...

Pharma marketers often underestimate the value of independent pharmacies.

Digital

Healthcare AI’s off switch needs a budget

An AI system can be cheap to buy and expensive to stop.

Digital

Sponsored

AI-enabled pharmacovigilance, with Updesh Dosanjh

Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.

Market Access

Chinese flag atop pills on black background

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Market Access

Two business hands outstretched, one weighing cash, the other drugs, for balance

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Oncology

In vivo CAR-T can solve the delivery problem – but solid tum...

A new generation of in vivo CAR-T cell technologies promises to remove some of the biggest practical barriers to conventional cell therapy.

Oncology

Unlocking the scalability of allogeneic CAR-T

Allogeneic CAR-T, built from healthy donor T-cells, offers a different path toward scale, accessibility, and consistency.

Oncology

Australia, CAR-T therapy, and solid tumours

Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.